DeepMed Research

Dydrogesterone

Generic Name: Dydrogesterone

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₂

CAS Number: 152-62-5

Unique Ingredient Identifier: 90I02KLE8K

Background: A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

Indication: Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.

Associated Conditions: Infertility, Menstrual Distress (Dysmenorrhea), Premenstrual Syndrome (PMS), Recurrent Miscarriages, Spontaneous Abortions

Associated Therapies: Assisted Reproductive Technology therapy, Menstrual Regulation

Clinical Trials

Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer

Not Applicable

Conditions: ART

Interventions: Drug: Dydrogesterone 10 MG
Drug: Endometrin 100Mg Vaginal Insert

First Posted Date: 2019-02-06

Last Posted Date: 2020-10-08

Lead Sponsor: Wolfson Medical Center

Target Recruit Count: 100

Registration Number: NCT03832699

Locations: 🇮🇱
Edith Wolfson Medical Center, Holon, Israel

Dydrogesterone in the Treatment of Endometrial Polyps

Phase 4

Completed

Conditions: Endometrial Polyp

Interventions: Drug: Dydrogesterone

First Posted Date: 2018-12-31

Last Posted Date: 2020-01-22

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT03790215

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Study of Real Clinical Practice to Evaluate the Effects of Oral Dydrogesterone for Treatment of Confirmed Endometriosis

Completed

Conditions: Endometriosis

Interventions: Drug: Duphaston® (Dydrogesterone)

First Posted Date: 2018-10-01

Last Posted Date: 2021-12-28

Lead Sponsor: Abbott

Target Recruit Count: 350

Registration Number: NCT03690765

Locations: 🇷🇺
FOTEK Medical Holding LLC, Women's Clinic, Ekaterinburg, Russian Federation
🇷🇺
Bashkir State Medical University, Ufa, Russian Federation
🇷🇺
South Ural State Medical University, Department of Obstetrics and Gynecology, Chelyabinsk, Russian Federation

and more 17 locations

Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF

Not Applicable

Recruiting

Conditions: ART
Infertility

Interventions: Drug: Duphaston
Drug: Cetrorelix

First Posted Date: 2018-09-21

Last Posted Date: 2024-08-20

Lead Sponsor: ShangHai Ji Ai Genetics & IVF Institute

Target Recruit Count: 784

Registration Number: NCT03680053

Locations: 🇨🇳
ShangHai JIAI Genetics&IVF Institute, Shanghai, China

Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI

Phase 4

Completed

Conditions: Genital Diseases, Female
Progesterone
Dydrogesterone
Physiological Effects of Drugs
Progestins
Hormones
Infertility, Female
Genital Diseases, Male
Infertility
Hormones, Hormone Substitutes, and Hormone Antagonists

Interventions: Drug: Dydrogesterone Oral Tablet
Drug: Micronized progesterone
Drug: Placebo Dydrogesterone oral tablet
Drug: Placebo Micronized progesterone

First Posted Date: 2018-09-19

Last Posted Date: 2020-12-17

Lead Sponsor: CRG UZ Brussel

Target Recruit Count: 30

Registration Number: NCT03677336

Locations: 🇧🇪
Centrum voor Reproductieve Geneeskunde, Jette, Brussel, Belgium

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

Phase 3

Completed

Conditions: Endometrial Hyperplasia Without Atypia

Interventions: Drug: Dydrogesterone 10 MG
Drug: Medroxyprogesterone Acetate

First Posted Date: 2018-09-18

Last Posted Date: 2023-02-17

Lead Sponsor: Xiaojun Chen

Target Recruit Count: 471

Registration Number: NCT03675139

Locations: 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai, China

Different Types of Progesterone in the Prevention of Preterm Labor

Phase 2

Conditions: Preterm Labor

Interventions: Drug: Oral dydrogesterone
Drug: 17 alpha hydroxyprogestrone caproate
Drug: Vaginal progesterone

First Posted Date: 2018-05-25

Last Posted Date: 2018-05-29

Lead Sponsor: Ain Shams University

Target Recruit Count: 140

Registration Number: NCT03537287

Locations: 🇪🇬
Ain SHams Maternity Hospital, Cairo, Abbaseya, Egypt

The Efficacy of Progestins in Treatment of Functional Ovarian Cyst

Early Phase 1

Conditions: Progesterone
Functional Ovarian Cyst

Interventions: Drug: Placebo Oral Tablet
Drug: Dydrogesterone 10 mg

First Posted Date: 2018-03-07

Last Posted Date: 2018-03-07

Lead Sponsor: Assiut University

Target Recruit Count: 90

Registration Number: NCT03456570

Progesterone to Prevent Preterm Delivery

Phase 2

Conditions: Preterm Birth

Interventions: Drug: Dydrogesterone Oral Tablet
Drug: Placebo Oral Tablet

First Posted Date: 2018-02-12

Last Posted Date: 2019-04-10

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 1714

Registration Number: NCT03428685

Locations: 🇨🇳
Department of Obstetrics and Gynaecology, Hong Kong, Hong Kong, China

Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion

Not Applicable

Conditions: Intrauterine Adhesion

Interventions: Device: disposable balloon uterine stent
Procedure: dried biological amnion graft
Drug: estradiol valerate tablets
Drug: dydrogesterone Tablets

First Posted Date: 2017-11-06

Last Posted Date: 2017-11-17

Lead Sponsor: Beijing Obstetrics and Gynecology Hospital

Target Recruit Count: 200

Registration Number: NCT03329898

Locations: 🇨🇳
Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy